Invention Grant
- Patent Title: Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
- Patent Title (中): 施用缺氧活化前药与Chk1抑制剂联合用于治疗癌症
-
Application No.: US14367168Application Date: 2012-12-20
-
Publication No.: US09254299B2Publication Date: 2016-02-09
- Inventor: Charles Hart , Fanying Meng , Jessica Sun
- Applicant: THRESHOLD PHARMACEUTICALS, INC.
- Applicant Address: US CA South San Francisco
- Assignee: Threshold Pharmaceuticals, Inc.
- Current Assignee: Threshold Pharmaceuticals, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Foley & Lardner LLP
- Agent Antoinette F. Konski; Photon Rao
- International Application: PCT/US2012/071074 WO 20121220
- International Announcement: WO2013/096687 WO 20130627
- Main IPC: A61K31/675
- IPC: A61K31/675 ; A61K31/4535 ; A61K31/5377 ; A61K31/5517 ; A61K31/34 ; A61K31/66 ; A61K45/06 ; A61K31/4168
Abstract:
Cancer can be treated by administration of TH-302 in combination with a Chk1 inhibitor.
Public/Granted literature
- US20150005263A1 ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR TREATING CANCER Public/Granted day:2015-01-01
Information query
